Myriad Genetics INC: management transactions · United States · SEC (Form 4)

About Myriad Genetics INC

Myriad Genetics Inc. is a U.S.-based molecular diagnostics and precision medicine company listed on the NASDAQ under the ticker MYGN, in the United States. Founded in the 1990s and historically rooted in Salt Lake City, Utah, Myriad has built a long-standing reputation as a science-led diagnostics provider focused on using genetic information to guide disease risk assessment, diagnosis, prognosis and treatment selection. Its business model is centered on proprietary laboratory testing, clinical evidence generation and deep engagement with healthcare providers. Management has said the company served more than 55,000 healthcare providers and delivered more than 1.5 million molecular diagnostic and precision medicine test results in 2025, underscoring a meaningful commercial footprint. ([myriad.com](https://myriad.com/about-myriad/myriad-around-the-world/?utm_source=openai)) The company’s revenue base is organized around four core categories: Hereditary Cancer, Tumor Profiling / Oncology, Prenatal and Mental Health. In hereditary cancer, flagship products include MyRisk and BRACAnalysis CDx. In oncology, Myriad markets MyChoice CDx, Prolaris, Precise Tumor and EndoPredict. In prenatal health, the main offerings include Foresight, Prequel, FirstGene and SneakPeek. In mental health, GeneSight remains the key pharmacogenomics platform. Myriad also participates in companion diagnostics and pharmaceutical partnerships, aiming to embed its tests into clinical workflows and treatment-development programs. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0000899923/000089992326000018/mygn-20251231.htm?utm_source=openai)) From a historical perspective, Myriad is one of the sector’s better-known pioneers. The company states that it helped discover the BRCA1/2 genes, launched BRACAnalysis in 1996, and developed one of the first prognostic tests for prostate cancer. That scientific heritage remains an important competitive asset. The company competes in a crowded diagnostics market against specialized molecular testing peers and larger healthcare groups with significant scale, R&D budgets and commercial reach. Myriad’s differentiation comes from clinical utility, brand recognition, proprietary data and a broad installed base of ordering physicians rather than from commoditized testing alone. ([myriad.com](https://myriad.com/about-myriad/myriad-around-the-world/?utm_source=openai)) Geographically, Myriad is still primarily exposed to the U.S. market, with its headquarters and major support operations in Salt Lake City, Utah, while maintaining selective international operations. Recent strategic milestones matter for investors. In 2024, the company acquired selected assets from Intermountain Precision Genomics, including Precise Tumor and Precise Liquid. In 2025, it announced a strategic collaboration with PATHOMIQ to add AI technology to its oncology portfolio, and a separate collaboration with SOPHiA GENETICS to develop a liquid-biopsy companion diagnostic offering. In 2026, Myriad outlined a more focused strategy centered on the Cancer Care Continuum, with planned product launches including Precise MRD, an AI-enabled Prolaris version and FirstGene. ([investor.myriad.com](https://investor.myriad.com/news-releases/news-release-detail/26041/?utm_source=openai))